

## Hepatitis C Virus (HCV) FibroSURE™

### Introduction

Liver biopsies have traditionally been used in the management of hepatitis C patients to provide important information about disease prognosis as well as about the likelihood of response to therapy.<sup>1,2</sup> A baseline biopsy is often used by physicians in determining the urgency for treatment in a given patient. Chronically infected HCV patients with mild hepatitis and limited fibrosis progress slowly or not at all during a 10- to 20-year period, while those with moderate and severe inflammation and fibrosis progress more rapidly to cirrhosis during a similar period.<sup>1,2</sup> Liver biopsy findings may have some usefulness in predicting efficacy of treatment in patients with chronic hepatitis C. Advanced fibrosis or cirrhosis on initial liver biopsy is associated with a decreased likelihood of sustained virologic response to treatment, although the predictive value is not sufficiently strong to withhold therapy for such patients.<sup>1,2</sup> Beyond current assessment and prognosis, the liver biopsy can provide baseline histology for future assessments of response to therapy and/or HCV disease progression.

Liver biopsy is an invasive procedure that is frequently accompanied by transient pain and may occasionally be associated with serious complications including hemorrhage, pneumothorax, or punctured viscera. For some patients, the requirement for a liver biopsy, with its associated expense as well as risks, becomes a barrier to initiation of therapy. Investigators have recently questioned the need for a liver biopsy and have been searching for alternative noninvasive biochemical markers that could be used as surrogate markers for a liver biopsy.<sup>2,3</sup> HCV FibroSURE™ (FibroTest/ActiTest), a newly developed six-biochemical marker index, correlates well with liver biopsy findings, as measured by Metavir fibrosis staging and necroinflammatory activity grading.<sup>4,5</sup> It provides an alternative for assessing liver status without the associated risk of an invasive procedure.

### Laboratory Method

HCV FibroSURE is a noninvasive blood test that combines the quantitative results of six serum biochemical markers,  $\alpha_2$ -macroglobulin, haptoglobin, apolipoprotein A<sub>1</sub>, bilirubin,  $\gamma$ -glutamyl transpeptidase (GGT), and ALT, with a patient's age and gender in a patented artificial intelligence algorithm to generate a measure of fibrosis and necroinflammatory activity in the liver. HCV FibroSURE is a continuous linear biochemical assessment of fibrosis stage and necroinflammatory activity grade. It provides a

numerical quantitative estimate of liver fibrosis ranging from 0.00 to 1.00 corresponding to the well-established Metavir scoring system of stages F0 to F4. (F0 = no fibrosis, F1 = portal fibrosis, F2 = bridging fibrosis with few septa, F3 = bridging fibrosis with many septa, F4 = cirrhosis).<sup>6</sup> In addition, the test provides a numerical quantitative estimate of necroinflammatory activity ranging from 0.00 to 1.00 corresponding to the Metavir scoring system of grades A0 to A3. (A0 = no activity, A1 = minimal activity, A2 = moderate activity, A3 = severe activity).<sup>6</sup>

### Clinical Utility

Using a patented algorithm analyzing six serum biochemical markers, HCV FibroSURE has been shown to lead to a reliable quantitative assessment of fibrogenic and inflammatory activity in the liver of HCV patients.<sup>4,5,8</sup> It provides an accurate measure of bridging fibrosis and/or moderate necroinflammatory activity with AUROC (Area Under Receiver-Operating Characteristic Curve) predictive values between 0.70 and 0.80 when compared with liver biopsy (0.5 being nonpredictive and 1.0 being 100% predictive).<sup>5</sup>

Discordance between liver biopsy and FibroTest/ ActiTest results were primarily due to sampling errors associated with small biopsies <15 mm and/or the presence of hemolysis leading to decreased haptoglobin levels and falsely elevated fibrosis and activity scores.<sup>5,7,8</sup> HCV FibroSURE AUROC values increased to 0.88 when analysis was limited to samples where biopsy size was >15 mm indicating greater concordance when biopsy sampling errors were reduced.<sup>5</sup>

In a recent publication by Poynard et al,<sup>9</sup> discordance of two or more stages between FibroTest and liver biopsy (n=154 discordant samples) was caused by errors in sampling or interpretation of the liver biopsy associated with biopsy size and steatosis more than 60% of the time (97/154) and to errors in the biochemical test in less than 10% of cases (13/154). The reason for the discordance could not be determined in 44/154 samples.<sup>9</sup> HCV FibroSURE can be used for

- Assessment of liver status following a diagnosis of HCV
- Baseline determination of liver status before initiating HCV therapy
- Posttreatment assessment of liver status six months after completion of therapy
- Noninvasive assessment of liver status in patients who are at increased risk of complications from a liver biopsy

HCV FibroSURE is not recommended for patients during combined interferon/ribavirin therapy, since ribavirin may induce hemolysis, low haptoglobin levels, and falsely elevated fibrosis and activity scores.<sup>5</sup> HCV FibroSURE should **not** be used for patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug-induced hepatitis, genetic liver disease, autoimmune hepatitis, and/or extrahepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

## References

1. Dienstag JL. The role of liver biopsy in chronic hepatitis C. *Hepatology*. 2002; 36:S152-S160.
2. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: A systematic review. *Hepatology*. 2002; 36: S161-S172.
3. Albanis E, Friedman SL. Noninvasive markers of hepatic fibrosis. *Clin Pers Gastroenterol*. 2002; 5:182-187.
4. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. *J Viral Hep*. 2002; 9:128-133.
5. Poynard T, McHutchison J, Manns M, Myers RB, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. *Hepatology*. 2003; 38:481-492.
6. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*. 1996; 24:289-293.
7. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology*. 2003; 38:1449-1457.
8. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatology*. 2004 Sep 23; 3(1):8-19.
9. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. *Clin Chem*. 2004; 50(8):1344-1355.

LabCorp and BioPredictive have entered into an exclusive agreement to offer HCV FibroSURE. Published literature that includes data on this test refers to the tests as FibroTest/ActiTest. HCV FibroSURE™ is a trademarked LabCorp name that combines both FibroTest and ActiTest as a single test option.

## Hepatitis C Virus (HCV) FibroSURE™ . . . . . 550123

**CPT** 83883; 83010; 82172; 82977; 82247; 84460

**Synonyms** HCV FibroSURE™; FibroSURE™; FibroTest; ActiTest

**Test Includes** FibroTest ( $\alpha_2$ -macroglobulin, haptoglobin, apolipoprotein A<sub>1</sub>, bilirubin,  $\gamma$ -glutamyl transpeptidase [GGT]); ActiTest ( $\alpha_2$ -macroglobulin, haptoglobin, apolipoprotein A<sub>1</sub>, bilirubin,  $\gamma$ -glutamyl transpeptidase [GGT], alanine aminotransferase [ALT])

**Special Instructions** Include patient's age and gender on request form.

**Specimen** Serum

**Volume** 3 mL

**Minimum Volume** 3 mL (**Note:** This volume does **not** allow for repeat testing.)

**Container** Red-stopper tube or gel-barrier tube

**Collection** Separate serum from cells within one hour of collection and refrigerate at 2°C to 8°C. **Protect from light.** Specimen is stable for as long as three days. Freeze if storage longer than 72 hours is needed.

**Storage Instructions** Refrigerate at 2°C to 8°C for as long as 72 hours; **freeze** if longer storage required.

**Patient Preparation** Patient should fast for at least eight hours.

**Causes for Rejection** Gross hemolysis; gross lipemia; improperly labeled specimen

### Reference Interval

$\alpha_2$ -macroglobulin	110-276 mg/dL
Haptoglobin	34-200 mg/dL
Apolipoprotein A <sub>1</sub>	110-205 mg/dL (female) 110-180 mg/dL (male)
Bilirubin, total	0.1-1.2 mg/dL
$\gamma$ -glutamyl transpeptidase (GGT)	0-65 IU/L
Alanine aminotransferase (ALT)	0-40 IU/L (female) 0-55 IU/L (male)

### Metavir Scoring System

#### Fibrosis Stage (FibroTest)

<b>F0</b> - No fibrosis	< 0.21
<b>F0 - F1</b>	0.21 - 0.27
<b>F1</b> - Portal fibrosis	0.27 - 0.31
<b>F1 - F2</b>	0.31 - 0.48
<b>F2</b> - Bridging fibrosis with few septa	0.48 - 0.58
<b>F3</b> - Bridging fibrosis with many septa	0.58 - 0.72
<b>F3 - F4</b>	0.72 - 0.74
<b>F4</b> - Cirrhosis	> 0.74

#### Activity Grade (ActiTest)

<b>A0</b> - No activity	< 0.17
<b>A0 - A1</b>	0.17 - 0.29
<b>A1</b> - Minimal activity	0.29 - 0.36
<b>A1 - A2</b>	0.36 - 0.52
<b>A2</b> - Moderate activity	0.52 - 0.60
<b>A2 - A3</b>	0.60 - 0.62
<b>A3</b> - Severe activity	> 0.62

**Use** Assessment of liver status following a diagnosis of HCV. Baseline determination of liver status before initiating HCV therapy. Posttreatment assessment of liver status six months after completion of therapy. Noninvasive assessment of liver status in patients who are at increased risk of complications from a liver biopsy.

**Methodology** Patented artificial intelligence algorithm combines patient's age, gender, and the results of six biomarkers to generate a measure of fibrosis and necroinflammatory activity in the liver.

**Contraindications** HCV FibroSURE should **not** be used for patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug-induced hepatitis, genetic liver disease, autoimmune hepatitis, and/or extrahepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.



www.LabCorp.com